✦ LIBER ✦

Randomized double-blinded placebo controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24 months clinical and MRI results

✍ Scribed by I. Millefiorim; C. Gasperini

Book ID: 119109318
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 136 KB
Volume: 56-63
Category: Article
ISSN: 0165-5728
DOI: 10.1016/0165-5728(95)98903-o

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized placebo-controlled trial of m

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

✍ E. Millefiorini; C. Gasperini; C. Pozzilli; F. D’Andrea; S. Bastianello; M. Troj 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 44 KB

Intravenous immunoglobulin treatment in

Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: A randomized, double-blind multicenter, placebo-controlled trial

✍ A. Achiron; R. Gilad; S. Hassin; Y. Barak; U. Gabbay; I. Ziv; Y. Goldhamer; E. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Neuropsychological performance during a

Neuropsychological performance during a double-blind, placebo-controlled trial of copolymer-1 in relapsing-remitting multiple sclerosis

✍ M. Grossman; K. Onishi; H. Thompson; M. D'Esposito; C. Armstrong; J. Cohen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Magnetic resonance imaging results of th

Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis

✍ David K. B. Li; Donald W. Paty 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

The PRISMS (Prevention of Relapses and Disability by Interferon-␤1a Subcutaneously in Multiple Sclerosis) trial was a doubleblind, randomized, multicenter, phase III, placebo-controlled study of interferon-␤1a in 560 patients from 22 centers in 9 countries with clinically definite or laboratory-supp

Glatiramer acetate in combination with m

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial

✍ Metz, L.; Li, D.; Traboulsee, A.; Myles, M.; Duquette, P.; Godin, J.; Constantin 📂 Article 📅 2009 🏛 SAGE Publications 🌐 English ⚖ 317 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro